Table 1.

Criteria for modification of chemotherapy

Adverse events	Suspension criteria		Resumption criteria	Dose reduction criteria
	FTD/TPI	Ramucirumab		FTD/TPI	Ramucirumab
Neutrophil count	< 1,000/mm3		≥ 1,500/mm3	< 500/mm3 and delayed for more than 7 days
Platelet count	< 50,000/mm3		≥ 75,000/mm3	< 50,000/mm3 and delayed for more than 7 days
Febrile neutropenia	Grade ≥ 3		resolved	Grade ≥ 3
Other adverse eventsa	Grade ≥ 3		Grade ≤ 1 or baseline	Grade ≥ 3
Urinary protein		≥ 2 g and < 3 g / day, or UPC ≥ 2.0 and < 3.0	≤ 1+ on dipstick or < 2 g/day, or UPC < 2.0		≥ 2 g and < 3 g / day, or UPC ≥ 2.0 and < 3.0
Hypertension		Symptomatic grade 2 or grade ≥ 3	Can be controlled with antihypertensive drugs		Symptomatic grade 2 or grade ≥ 3
Other adverse eventsb		Grade ≥ 3	Grade ≤ 1 or baseline	Grade ≥ 3	Grade ≥ 3 (second episode)

FTD/TPI: trifluridine tipiracil

UPC: urine protein/urine creatinine ratio

^a : FTD/TPI related, except in the case where the event is not serious and where safe use of the drug can continue.

^b : Ramucirumab related, except in the case where the event is not serious and safe use of the drug can continue.